Prime Insights

    Drug trends

April 6, 2017 | Prime Therapeutics

Prime releases 2017 Drug Trend Reports

Prime is creating partnerships and programs that will reshape the PBM industry. These reports illustrate the powerful results that this work can generate.

Get the highlights

Nov. 8, 2016 | Prime Therapeutics

By the numbers: Managing accelerating autoimmune drugs costs across benefits is critical

Prime’s pharmacist researchers studied integrated trends in autoimmune drug use and spend, and presented their findings at the Academy of Managed Care Pharmacy (AMCP) 2016 Nexus event. Get the highlights — and learn what plan sponsors can do.

Trends in autoimmune

July 20, 2016 | Cathy Starner, PharmD, BCPS

America’s opioid epidemic: Part 5 — the future of safer opioid use

The opioid crisis is staggering, but steps are being taken in the right direction. What will tomorrow hold for safer opioid use?

Important work being done on the opioid front

July 12, 2016 | Cathy Starner

America’s opioid epidemic: Part 4 — fighting overuse through legislation, advocacy and political action

Solving the opioid crisis goes beyond the private sector. To drive meaningful change, health care, government and industry groups all have to work together.  

Evidence-based policies that could help combat the crisis

July 8, 2016 | Cathy Starner

America’s opioid epidemic: Part 3 — strategies for curbing abuse

Combating the opioid crisis requires a full set of tools — and proof that they work. See how the research stacks up. 

Strategies to keep members safe and control the total cost of care

July 5, 2016 | Cathy Starner

America’s opioid epidemic: Part 2 — adding it up

To address the problem, we first have to gauge it. Prime’s researchers have worked to pinpoint who’s at highest risk for harm from controlled substances, such as opioids, and how this use potentially impacts the total cost of care. 

How can plan sponsors find high-risk users, and how does use impact the cost of care?

June 28, 2016 | Cathy Starner

America’s opioid epidemic: Part 1 — diagnosing the problem

Opioid drugs are killing more Americans than ever. Every health care stakeholder must take action. Prime explores the ins and outs of opioid overuse and management in our latest five-part series.

Who's using opioids, and who can help curb this deadly trend?

April 29, 2016 | Kevin Bowen

4.5-year study finds diabetes and related drug costs surging

By 2050, as many as 1 in 3 adults in the United States will have diabetes. Coupled with drug price inflation, rising diabetic drug use has led to mounting costs for plan sponsors. To help measure the impact of rising use and costs, our team dove deep into Prime’s data to study diabetes prevalence, incidence and drug therapy.

What we learned | Study poster

Dec. 23, 2015 | Prime Therapeutics

REPORT: Defining parallels

As the Health Insurance Marketplace (HIM) matures into its second year, we’ve discovered a number of interesting parallels — and a few significant differences — in the way public exchange members use medicines and accumulate drug spend.

Report summary  | Full report

Aug. 15, 2015 | Prime Therapeutics

REPORT: 2014 prescription drug cost report — Defining dynamics

Prime Therapeutics (Prime) is pleased to announce our 2014 Report on prescription drug costs. This year, our definition of “drug trend” has evolved to reflect the change in net prescription costs. These costs offer the clearest picture of where costs start and how they compare.

Report summary | Full report

June 1, 2015 | Prime Therapeutics

REPORT: Defining variance

Our new white paper, Defining variance, dives deeper into Health Insurance Marketplace data. In it, we explore differences in demographics, use and spend within the five different levels of coverage — identified as “metallic levels.” This analysis revealed more detailed insights and distinctions — and also a few surprises.

Report summary | Full report

 June 17, 2014 | Prime Therapeutics

REPORT: Prescription drug cost report — Looking back, moving forward

Prime Therapeutics is pleased to introduce our yearly look back at commercial pharmacy costs and spending trends from the previous year. We’ve renamed our annual trend publication to reflect the inclusion of net ingredient costs. Ingredient cost offers the clearest picture of where costs start and how they compare.

Report summary | Full report

June 17, 2014 | Prime Therapeutics

INFOGRAPHIC: Spotlight on specialty

Spending on specialty medicines is growing quickly. Prime projects that ten years from today, these high-cost medicines could represent one quarter of all health care costs. How much do you know about these drugs? Our new infographic can quickly get you up to speed.